Cannabinoid Receptor Type 1 Availability in Individuals with a History of Childhood Trauma: A Positron Emission Tomography Study

Cannabinoid Receptor Type 1 Availability in Individuals with a History of Childhood Trauma: A Positron Emission Tomography Study | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Cannabinoid Receptor Type 1 Availability in Individuals with a History of Childhood Trauma: A Positron Emission Tomography Study ANAHITA BASSIR NIA, Ardavan Mohammad Aghaei, Brian Pittman, Nachshon Korem, and 5 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-6536815/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted 10 You are reading this latest preprint version Abstract Early life adversity has a lasting impact on the endocannabinoid (eCB) system based on animal models. However, the impact of early life adversity such as childhood trauma (CT) on the eCB system has not been thoroughly studied. We assessed the availability of cannabinoid receptor type 1 (CB1R) in individuals with CT compared to healthy controls without CT (HCs). Cannabinoid receptor type 1 (CB1R) availability was compared in adults with CT (N = 22) and age- and sex-matched HCs (n = 22), using positron emission tomography (PET) imaging with the CB1R-specific radiotracer [ 11 C]OMAR. Using linear models, the effect of the group was assessed on global and trauma-relevant brain regions (amygdala, hippocampus, and frontal cortex). Compared to HCs, lower CB1R availability was observed in CT globally (difference= -11.36%, F (1,42) = 4.35, p = 0.04), in amygdala (-13.70%, F (1,84) = 6.66, p = 0.01), and in hippocampus (-14.50%, F (1,84) = 6.59, p = 0.01), but not in frontal cortex (-8.08%, F (1,84) = 2.17, p = 0.14). There were no effects of a diagnosis of posttraumatic stress disorder, major depressive disorder, nicotine dependence, or the use of antidepressant medication. This preliminary result of lower CB1R availability in adults with CT compared with HCs suggests eCB dysregulation associated with CT. Future studies should replicate and extend this finding and examine the potential effects of various trauma features on the eCB system. Health sciences/Biomarkers Biological sciences/Neuroscience Figures Figure 1 Introduction Childhood trauma (CT), defined as exposure to significant traumatic events before the age of 18, has profound impacts on mental health [ 1 ]. Individuals who experience CT are at higher risk of developing several psychiatric disorders, including depression and post-traumatic stress disorder (PTSD) [ 2 , 3 ]. CT exposure has been reported to lead to structural and functional alterations in the nervous system, resulting in long-lasting consequences [ 4 – 7 ]. CT typically imposes threats to survival, body integrity, or sense of self, which explains the significant alterations in the ‘threat-detection and response circuit’, particularly the hippocampus, amygdala, and prefrontal cortex (PFC), in individuals with a history of CT [ 7 ]. The endocannabinoid (eCB) system, which has a central role in stress response [ 8 ], is impacted by various forms of trauma and chronic stress [ 9 – 13 ]. Trauma-induced reductions in cannabinoid receptor type 1 (CB1R), the most abundant G-protein coupled receptor in the brain, have been reported in animal models of early life adversity, such as maternal deprivation and social isolation [ 14 , 15 ]; these findings persist into adulthood [ 16 ]. Similarly, animal models of chronic stress have reported lower levels of CB1Rs in various brain regions, including the hippocampus [ 9 – 13 ]. Despite this evidence from animal studies, the exact impact of CT on the eCB system in humans remains unclear. Human studies on the impact of trauma on the eCB system have predominantly focused on peripheral eCB levels and reported lower peripheral levels of 2-arachidonoyl glycerol (2-AG) and Anandamide (AEA) in those with trauma-related psychiatric disorders [ 17 – 19 ]. However, they often did not specifically address CT. In contrast, a few studies that investigated peripheral eCBs in individuals with CT reported higher hair levels of 1-arachidonoylglycerol (1-AG) [ 20 ], and higher plasma levels of an eCB-related compound, oleoylethanolamide (OEA) [ 21 ]. While these studies provide valuable evidence on the unique long-lasting impact of CT on the eCB system, peripheral eCB levels can originate from various sources [ 22 ], and are not correlated with central eCBs [ 23 ]. The impact of CT on the central eCB system in humans has not been reported. CB1Rs are principal components of the eCB system that can be measured in vivo using PET imaging and the CB1R specific radiotracers, such as [11C]OMAR [ 24 – 27 ]. In this study, for the first time, we aimed to compare CB1R availability in adult humans with and without CT histories. Consistent with evidence from animal models [ 14 , 15 ], we hypothesized to observe a lower CB1R availability in individuals with a history of CT versus healthy controls with no history of CT (HC), both at a whole-brain level, and in three specific brain regions that express high levels of CB1R and are largely affected by CT, i.e., amygdala, hippocampus, and frontal cortex [ 28 ]. Methods Participants: Adult men and women (age ≥ 18) with CT histories (n=22) comprised a CT group, and age- and sex-matched healthy individuals without CT histories served as the HC group (n=22). All individuals received detailed information about the study and signed written informed consent. Inclusion in the CT group was determined based on exposure to a major traumatic event based on Criterion A of the DSM-5 criteria for PTSD, assessed by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) or Structured Clinical Interview for DSM-5 Disorders (SCID-5), and exposure to traumatic events for the first time before the age of 18, assessed by the Trauma Questionnaire (TQ) and Childhood Trauma Questionnaire (CTQ) [29-32]. Nicotine dependence was assessed using the Fagerstrom Test for Nicotine Dependence (FTND) [33]. Exclusion criteria included severe mental illness (e.g., schizophrenia), current substance use disorder (excluding nicotine), recent cannabis use, use of anticoagulants, and any medical condition that could interfere with the study, as determined by the primary investigator. The study protocol was approved by the institutional review boards of Yale School of Medicine and the VA Connecticut Health Care System. Additional HCs were included from our group’s previously published research investigating CB1R availability in individuals with other psychiatric disorders [34, 35]. Radiochemistry and Imaging: Eligible participants underwent structural Magnetic Resonance Imaging (MRI) using a Siemens 3T system (Siemens Medical Solutions, Malvern, Pennsylvania). Standard T1-weighted anatomical sequences were obtained to exclude anatomical abnormalities and to co-register with PET scan images. [ 11 C]OMAR, a specific CB1R tracer, was used to measure CB1R availability. [ 11 C]OMAR was synthesized with high molar activity according to a previously published protocol adapted to the TRACERlab FXC Pro automated synthesis module (GE Healthcare, Milwaukee, WI) [36]. Dynamic PET scans were acquired using a High Resolution Research Tomograph (HRRT, Siemens Medical Systems, Knoxville, TN) in 3D mode. Imaging started with a six-minute transmission scan used for attenuation correction. Subsequently, participants were scanned for 120 minutes following an intravenous bolus injection of 12.8 (4.16) mCi [ 11 C]OMAR over a period of one minute. To account for motion, an optical system (Polaris Vicra, Northern Digital Incorporated, Waterloo, Ontario, Canada) was positioned behind the PET scanner to track the position of an infrared reflective tool mounted on the participant’s head. An arterial line was placed prior to the scan with arterial blood sampling acquired throughout the imaging session. Blood samples collected at 5, 15, 30, 60, 90, and 120 minutes post-injection were analyzed using column-switching high-performance liquid chromatography (HPLC) to measure the unmetabolized parent tracer fraction for calculation of the metabolite-corrected arterial plasma input function [37, 38]. Image Processing: Consistent with previous work, dynamic list mode data were reconstructed and corrected for attenuation, normalization, scatter, randoms, dead time, and motion using the ordered subset-expectation maximization (OSEM) algorithm [39]. Subsequently, PET images were registered to the participant’s MR anatomical image and then to an MR template image [40]. Anatomical Automatic Labeling (AAL) was used to define thirteen regions of interest (ROIs), namely amygdala, caudate, cerebellum, anterior cingulate cortex, posterior cingulate cortex, frontal, hippocampus, insula, occipital, parietal, putamen, temporal, and thalamus [41]. Partial volume correction was also applied using a method similar to previous studies [40, 42]. Time-activity curves for each ROI were extracted, and multilinear analysis-1 (t* = 30 min) was used to estimate [ 11 C]OMAR V T in each region [43]. Statistical Analysis: All outcomes were assessed for normality using normal probability plots and Kolmogorov-Smirnov tests. Similar to previous studies [19, 34, 44], a global composite of CB1R availability was calculated by averaging [ 11 C]OMAR V T across all 13 study regions and served as a primary outcome and was compared between groups (CT vs HC) using a linear model. Additionally, three ROIs (amygdala, frontal cortex, and hippocampus) were selected as primary outcomes, given the evidence on the heavy impact of CT on these regions [7]. These were analyzed using a linear mixed model (LMM) with group as a between-subjects factor and region as a within-subjects factor. The interaction was modeled, and the correlation between observations measured repeatedly within each subject was modeled using structured variance-covariance matrices. The best-fitting model was selected according to information criteria, and residual plots confirmed model fit. Least-square (LS) means were estimated and compared post-hoc. The rest of the ten ROIs were considered as exploratory outcomes and were analyzed using similar LMMs. Previous studies have suggested that age, sex, and body mass index (BMI) relate to CB1R availability in some ROIs [40]; therefore, these were assessed in each model. However, their inclusion did not alter the model results and had no significant effect on the outcomes, and thus, they were dropped from the model for parsimony. Potential effects of clinical factors within CT (current psychiatric diagnosis, medication use, number of trauma events, nicotine dependence) on global CB1R were assessed using similar linear models as described above. All primary outcomes were tested using a two-sided alpha=0.05 significance threshold. For exploratory analyses testing for group differences in secondary regions and for the effects of clinical factors within the CT group, Type I error was corrected using the less conservative step-down (SD) Sidak adjustment [45]. All analyses were conducted using SAS, version 9.4 (SAS Institute Inc., Cary, NC, USA). Results Baseline characteristics. Age, sex, BMI, and the dose and mass of the tracer injected during the PET imaging were similar between groups (Table 1). Of the 22 participants with CT, 8 met criteria for current posttraumatic stress disorder (PTSD), and 7 met criteria for current major depressive disorder (MDD, 6 of whom had both MDD and PTSD) (based on SCID-5). Six individuals with CT were taking antidepressant medications. CB1R availability in the CT versus HC groups. Lower composite CB1R availability was observed in the CT versus HC groups (difference -11.36%, F (1,42) =4.35; p = 0.04, d = 0.63). In the LMM examining the pre-selected 3 PTSD-relevant ROIs, the group-by-region interactions was significant ( F (2,84) =4.49, p=0.014) driving by lower CB1R availability among CT participants in the amygdala (-13.70%, F (1,84) =6.66, p=0.01, d=0.72) and hippocampus (-14.50%, F (1,84) =6.59, p=0.01, d=0.78), but not in the frontal region (-8.08%, F (1,84) =2.17, p=0.14, d=0.47) (Figure1). In the exploratory analysis of other ROIs, no statistically significant differences were observed (Table 2). The effect of clinical factors on global CB1R availability among CT There was no difference in CB1R availability based on meeting criteria for PTSD ( F (1,20) =4.01, p SD Sidak =0.27) or MDD ( F (1,20) =4.11, p SD Sidak =0.27). On average, CT participants reported encountering 19.0 ± 33.4 traumatic events in their lifetime, and event frequency was not associated with CB1R availability (Spearman r = -0.05, p SD Sidak = 0.84). No differences were observed between participants who were or were not taking antidepressant medications ( F (1,20) =2.63, p SD Sidak =0.32). While there was no significant difference in CB1R availability between tobacco users and non-users ( F (1,20) =0.51, p SD Sidak =0.71), this result should be interpreted with caution, as only two CT participants reported smoking. Discussion Whole-brain CB1R availability is lower in adults with a history of CT compared to controls with a reduction in specific regions, including the hippocampus and amygdala. To the best of our knowledge, this is the first report on the in vivo CB1R availability in adult humans with CT. Our main finding aligns with most preclinical studies that have reported lower CB1R immunoreactivity, expression levels, or binding following early life stressors in various brain regions, especially the hippocampus, with findings persisting into adulthood [ 14 , 46 – 48 ]. However, not all preclinical studies have reported such findings [ 16 , 49 ]. Both animal and human studies have demonstrated that CB1R expression gradually increases during early childhood, reaches its maximum in adolescence, and then drops to stable levels in early adulthood [ 50 ]. Thus, exposure to CT, when the eCB system is still immature, could disrupt the normal development of the main elements of the eCB system, such as CB1R. In addition, the eCB system and the hypothalamic-pituitary-adrenal (HPA) axis interact closely in the initiation and termination of stress responses [ 51 ]. CT has been shown to dysregulate the coupling of the glucocorticoid and eCB systems, leading to impaired regulation of stress responses by glucocorticoids [ 52 ]. Chronic stress typically induces downregulation of presynaptic CB1Rs, which is likely due to the activation of genomic glucocorticoid receptors and could be blocked by glucocorticoid receptor antagonists [ 12 , 13 ]. While the precise mechanisms for glucocorticoid receptor activation leading to downregulation of CB1Rs are not fully understood, two mechanisms have been proposed [ 8 ]: 1) direct negative regulation of the CB1R gene by glucocorticoids [ 53 ], or 2) glucocorticoid-mediated recruitment of eCB signaling, resulting in agonist-induced receptor desensitization, as observed with sustained 2-AG signaling elevation [ 54 ]. Considerable research has focused on the potential role of epigenetic programming in the delayed effects of CT on the eCB system. These studies generally indicate that CT has a persistent impact on gene expression and behavior through epigenetic mechanisms, with the HPA axis and glucocorticoid receptors being among the most consistently affected systems. A systematic review reported that CT, both in animal models and human studies, results in increased methylation and lower expression of glucocorticoid receptors [ 55 ]. This implies glucocorticoid resistance and dysregulation of the HPA axis response to stress in adulthood [ 55 , 56 ]. Other studies indicate that CT impairs the coupling of the glucocorticoid and eCB systems in the hippocampus, resulting in impaired stress regulation later in life [ 52 ]. Moreover, genetic studies have found significant interactions between CT, particularly sexual abuse, and eCB-related gene polymorphisms in amygdala-related stress habituation and symptoms of cannabis use disorder [ 57 , 58 ]. Our findings support the potential specific impact of CT on the eCB system, which may differ from the effects of trauma exposure when it occurs during adulthood. Future directions: Further studies are required to replicate these findings and investigate the clinical implications of low CB1R availability in individuals with a history of CT. The availability of cannabinoids and the recent development of eCB modulators make it possible now to target the eCB system in recovery from CT [ 59 ]. Moreover, given the critical development of the eCB system in adolescence, future studies should investigate the differential impact of trauma exposure during early childhood versus adolescence. The effects of other factors, such as the cumulative effects of major traumatic events and chronic stress, or the types of trauma, are also important to investigate. Limitations Study limitations warrant consideration. First, the sample size was small, but within the range of other published exploratory PET imaging studies on the eCB system [ 19 , 34 , 44 ]. Nevertheless, these preliminary findings warrant further research with larger sample sizes and more granular information on CT to investigate the impact of various trauma-related factors. Second, the small sample size did not allow for the investigation of sex differences. Sex differences in the eCB system and stress responses have been reported [ 60 ]. Future research should address potential sex differences in CB1R availability among individuals with CT histories. Third, not all HC participants completed questionnaires related to childhood trauma, and the extent of childhood trauma was not fully assessed in all cases. However, any history of CT in a subset of the HCs would likely attenuate rather than inflate the main findings. Lastly, we did not investigate the clinical impact of lower CB1R availability in individuals with CT histories. Further studies are needed to examine how low CB1R availability in individuals with CT histories may relate to stress responses or clinical symptoms. Conclusions This exploratory study showed lower CB1R availability in individuals with a history of CT, raising the intriguing possibility of targeting the eCB in the treatment of CT consequences on mental health. Declarations Acknowledgments This work was supported by the National Center for PTSD (NCPTSD), VA Healthcare Medical Center, National Institute of Drug Abuse Grant No. 21DA030702-01A1, National Institute of Mental Health Grant No. R21MH094961, and VA CSR&D Merit Award CX-001538. Conflict of Interest Anahita Bassir Nia is a member of the Scientific Advisory Board of Synendos Therapeutics AG, Switzerland. Marc Potenza has consulted for Boehringer Ingelheim and Baria-Tek; has been involved in a patent application with Yale University and Novartis; has received research support (to Yale) from Mohegan Sun Casino and the Connecticut Council on Problem Gambling; has participated in surveys, mailings, or telephone consultations related to internet use, addictions, impulse-control disorders or other health topics; has consulted for and/or advised gambling, non-profit, healthcare and legal entities on issues related to impulse control, internet use and addictive disorders; has performed grant reviews for research funding agencies; has edited journals and journal sections; has given academic lectures in grand rounds, CME events, and other clinical or scientific venues; and has generated books or book chapters for publishers of mental health texts. Deepak Cyril D’Souza currently receives or has received research support in the past 3 years from Takeda, Boehringer Ingelheim, Jazz, Biogen, and Cerevel, administered through Yale University School of Medicine. Deepak Cyril D’Souza has served as a consultant for Jazz, Bio Haven, Atai, Abide, France Foundation currently or in the past 3 years. Patents: 1) Emmanuelle Schindler and Deepak Cyril D’Souza: Use of Psilocybin in Headache Disorders, 2) Deepak Cyril D’Souza: Use of Dimethyltryptamine in the treatment of Depression. Ilan Harpaz-Rotem receives funding from Boehringer Ingelheim via Investigator-Initiated Research (IIR) for Precision Psychiatry. The rest of the authors have no financial conflicts of interest to report. References Lippard ETC, Nemeroff CB. The Devastating Clinical Consequences of Child Abuse and Neglect: Increased Disease Vulnerability and Poor Treatment Response in Mood Disorders. Am J Psychiatry 2020; 177 (1) : 20-36. Sun J, Patel F, Rose-Jacobs R, Frank DA, Black MM, Chilton M. Mothers’ adverse childhood experiences and their young children’s development. American journal of preventive medicine 2017; 53 (6) : 882-891. Brady KT, Back SE. Childhood trauma, posttraumatic stress disorder, and alcohol dependence. Alcohol research: current reviews 2012; 34 (4) : 408. Anacker C, O'Donnell KJ, Meaney MJ. Early life adversity and the epigenetic programming of hypothalamic-pituitary-adrenal function. Dialogues in clinical neuroscience 2014; 16 (3) : 321-333. Danese A, Moffitt TE, Harrington H, Milne BJ, Polanczyk G, Pariante CM et al. Adverse childhood experiences and adult risk factors for age-related disease: depression, inflammation, and clustering of metabolic risk markers. Archives of pediatrics & adolescent medicine 2009; 163 (12) : 1135-1143. Danese A, McEwen BS. Adverse childhood experiences, allostasis, allostatic load, and age-related disease. Physiology & behavior 2012; 106 (1) : 29-39. Teicher MH, Samson JA, Anderson CM, Ohashi K. The effects of childhood maltreatment on brain structure, function and connectivity. Nat Rev Neurosci 2016; 17 (10) : 652-666. Morena M, Patel S, Bains JS, Hill MN. Neurobiological Interactions Between Stress and the Endocannabinoid System. Neuropsychopharmacology 2016; 41 (1) : 80-102. Hill MN, Patel S, Carrier EJ, Rademacher DJ, Ormerod BK, Hillard CJ et al. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 2005; 30 (3) : 508-515. Hill MN, Carrier EJ, McLaughlin RJ, Morrish AC, Meier SE, Hillard CJ et al. Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. J Neurochem 2008; 106 (6) : 2322-2336. Hu W, Zhang M, Czéh B, Zhang W, Flügge G. Chronic restraint stress impairs endocannabinoid mediated suppression of GABAergic signaling in the hippocampus of adult male rats. Brain Res Bull 2011; 85 (6) : 374-379. Wamsteeker JI, Kuzmiski JB, Bains JS. Repeated stress impairs endocannabinoid signaling in the paraventricular nucleus of the hypothalamus. J Neurosci 2010; 30 (33) : 11188-11196. Rossi S, De Chiara V, Musella A, Kusayanagi H, Mataluni G, Bernardi G et al. Chronic psychoemotional stress impairs cannabinoid-receptor-mediated control of GABA transmission in the striatum. J Neurosci 2008; 28 (29) : 7284-7292. Suárez J, Llorente R, Romero-Zerbo SY, Mateos B, Bermúdez-Silva FJ, de Fonseca FR et al. Early maternal deprivation induces gender-dependent changes on the expression of hippocampal CB(1) and CB(2) cannabinoid receptors of neonatal rats. Hippocampus 2009; 19 (7) : 623-632. Alteba S, Korem N, Akirav I. Cannabinoids reverse the effects of early stress on neurocognitive performance in adulthood. Learning & Memory 2016; 23 (7) : 349-358. Robinson SA, Loiacono RE, Christopoulos A, Sexton PM, Malone DT. The effect of social isolation on rat brain expression of genes associated with endocannabinoid signaling. Brain Res 2010; 1343: 153-167. Hill MN, Bierer LM, Makotkine I, Golier JA, Galea S, McEwen BS et al. Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the World Trade Center attacks. Psychoneuroendocrinology 2013; 38 (12) : 2952-2961. Hill MN, Miller GE, Ho WS, Gorzalka BB, Hillard CJ. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry 2008; 41 (2) : 48-53. Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng M-Q, Gujarro-Anton A et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Molecular psychiatry 2013; 18 (9) : 1034-1040. Koenig AM, Gao W, Umlauft M, Schury K, Reister F, Kirschbaum C et al. Altered hair endocannabinoid levels in mothers with childhood maltreatment and their newborns. Biol Psychol 2018; 135: 93-101. Schaefer C, Enning F, Mueller JK, Bumb JM, Rohleder C, Odorfer TM et al. Fatty acid ethanolamide levels are altered in borderline personality and complex posttraumatic stress disorders. Eur Arch Psychiatry Clin Neurosci 2014; 264 (5) : 459-463. Hillard CJ. Circulating Endocannabinoids: From Whence Do They Come and Where are They Going? Neuropsychopharmacology 2018; 43 (1) : 155-172. Minichino A, Senior M, Brondino N, Zhang SH, Godwlewska BR, Burnet PWJ et al. Measuring Disturbance of the Endocannabinoid System in Psychosis: A Systematic Review and Meta-analysis. JAMA Psychiatry 2019; 76 (9) : 914-923. Wong DF, Kuwabara H, Horti AG, Raymont V, Brasic J, Guevara M et al. Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. Neuroimage 2010; 52 (4) : 1505-1513. Normandin MD, Zheng MQ, Lin KS, Mason NS, Lin SF, Ropchan J et al. Imaging the cannabinoid CB1 receptor in humans with [11C]OMAR: assessment of kinetic analysis methods, test-retest reproducibility, and gender differences. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2015; 35 (8) : 1313-1322. Tsujikawa T, Zoghbi SS, Hong J, Donohue SR, Jenko KJ, Gladding RL et al. In vitro and in vivo evaluation of (11)C-SD5024, a novel PET radioligand for human brain imaging of cannabinoid CB1 receptors. Neuroimage 2014; 84: 733-741. Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng MQ, Gujarro-Anton A et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry 2013; 18 (9) : 1034-1040. Harnett NG, Goodman AM, Knight DC. PTSD-related neuroimaging abnormalities in brain function, structure, and biochemistry. Experimental neurology 2020; 330: 113331. Weathers FW, Bovin MJ, Lee DJ, Sloan DM, Schnurr PP, Kaloupek DG et al. The Clinician-Administered PTSD Scale for DSM–5 (CAPS-5): Development and initial psychometric evaluation in military veterans. Psychological assessment 2018; 30 (3) : 383. First MB, Williams JBW, Karg RS, Spitzer RL. Structured clinical interview for DSM-5 disorders: SCID-5-CV research version . American Psychiatric Association Publishing Washington, DC2015. Bernstein DP, Fink L, Handelsman L, Foote J. Childhood trauma questionnaire. Assessment of family violence: A handbook for researchers and practitioners 1998. Davidson J, Smith R. Traumatic experiences in psychiatric outpatients. Journal of traumatic stress 1990; 3: 459-475. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerström test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. British journal of addiction 1991; 86 (9) : 1119-1127. D'Souza DC, Cortes-Briones JA, Ranganathan M, Thurnauer H, Creatura G, Surti T et al. Rapid Changes in CB1 Receptor Availability in Cannabis Dependent Males after Abstinence from Cannabis. Biol Psychiatry Cogn Neurosci Neuroimaging 2016; 1 (1) : 60-67. Neumeister A, Normandin MD, Murrough JW, Henry S, Bailey CR, Luckenbaugh DA et al. Positron emission tomography shows elevated cannabinoid cb 1 receptor binding in men with alcohol dependence. Alcoholism: Clinical and Experimental Research 2012; 36 (12) : 2104-2109. Horti AG, Fan H, Kuwabara H, Hilton J, Ravert HT, Holt DP et al. 11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors. Journal of Nuclear Medicine 2006; 47 (10) : 1689-1696. Normandin MD, Zheng M-Q, Lin K-S, Mason NS, Lin S-F, Ropchan J et al. Imaging the cannabinoid cb1 receptor in humans with [11c] omar: assessment of kinetic analysis methods, test–retest reproducibility, and gender differences. Journal of Cerebral Blood Flow & Metabolism 2015; 35 (8) : 1313-1322. Hilton J, Yokoi F, Dannals RF, Ravert HT, Szabo Z, Wong DF. Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl Med Biol 2000; 27 (6) : 627-630. Design of a motion-compensation OSEM list-mode algorithm for resolution-recovery reconstruction for the HRRT. Proceedings of the Nuclear Science Symposium Conference Record, 2003 IEEE 2003. IEEE. Radhakrishnan R, Worhunsky PD, Zheng M-Q, Najafzadeh S, Gallezot J-D, Planeta B et al. Age, gender and body-mass-index relationships with in vivo CB1 receptor availability in healthy humans measured with [11C] OMAR PET. NeuroImage 2022; 264: 119674. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002; 15 (1) : 273-289. Giovacchini G, Lerner A, Toczek MT, Fraser C, Ma K, DeMar JC et al. Brain Incorporation of 11C-Arachidonic Acid, Blood Volume, and Blood Flow in Healthy Aging: A Study With Partial-Volume Correction. Journal of Nuclear Medicine 2004; 45 (9) : 1471-1479. Ichise M, Toyama H, Innis RB, Carson RE. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2002; 22 (10) : 1271-1281. Ranganathan M, Cortes-Briones J, Radhakrishnan R, Thurnauer H, Planeta B, Skosnik P et al. Reduced Brain Cannabinoid Receptor Availability in Schizophrenia. Biol Psychiatry 2016; 79 (12) : 997-1005. Holland BS, Copenhaver MD. An improved sequentially rejective Bonferroni test procedure. Biometrics 1987 : 417-423. Romano-López A, Méndez-Díaz M, Ruiz-Contreras AE, Carrisoza R, Prospéro-García O. Maternal separation and proclivity for ethanol intake: a potential role of the endocannabinoid system in rats. Neuroscience 2012; 223: 296-304. Hill MN, Eiland L, Lee TTY, Hillard CJ, McEwen BS. Early life stress alters the developmental trajectory of corticolimbic endocannabinoid signaling in male rats. Neuropharmacology 2019; 146: 154-162. Lee TT, Hill MN. Age of stress exposure modulates the immediate and sustained effects of repeated stress on corticolimbic cannabinoid CB₁ receptor binding in male rats. Neuroscience 2013; 249: 106-114. Marco EM, Echeverry-Alzate V, López-Moreno JA, Giné E, Peñasco S, Viveros MP. Consequences of early life stress on the expression of endocannabinoid-related genes in the rat brain. Behav Pharmacol 2014; 25 (5-6) : 547-556. Bara A, Ferland JN, Rompala G, Szutorisz H, Hurd YL. Cannabis and synaptic reprogramming of the developing brain. Nat Rev Neurosci 2021; 22 (7) : 423-438. Hill MN, Campolongo P, Yehuda R, Patel S. Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder. Neuropsychopharmacology 2018; 43 (1) : 80-102. Atsak P, Morena M, Schoenmaker C, Tabak E, Oomen CA, Jamil S et al. Glucocorticoid-endocannabinoid uncoupling mediates fear suppression deficits after early - Life stress. Psychoneuroendocrinology 2018; 91: 41-49. Mailleux P, Vanderhaeghen JJ. Glucocorticoid regulation of cannabinoid receptor messenger RNA levels in the rat caudate-putamen. An in situ hybridization study. Neurosci Lett 1993; 156 (1-2) : 51-53. Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG et al. Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci 2010; 13 (9) : 1113-1119. Turecki G, Meaney MJ. Effects of the Social Environment and Stress on Glucocorticoid Receptor Gene Methylation: A Systematic Review. Biol Psychiatry 2016; 79 (2) : 87-96. Klengel T, Binder EB. Epigenetics of Stress-Related Psychiatric Disorders and Gene × Environment Interactions. Neuron 2015; 86 (6) : 1343-1357. Carey CE, Agrawal A, Zhang B, Conley ED, Degenhardt L, Heath AC et al. Monoacylglycerol lipase (MGLL) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala habituation: Evidence from an endocannabinoid system-level analysis. J Abnorm Psychol 2015; 124 (4) : 860-877. Lazary J, Eszlari N, Juhasz G, Bagdy G. Genetically reduced FAAH activity may be a risk for the development of anxiety and depression in persons with repetitive childhood trauma. Eur Neuropsychopharmacol 2016; 26 (6) : 1020-1028. Mayo LM, Rabinak CA, Hill MN, Heilig M. Targeting the Endocannabinoid System in the Treatment of Posttraumatic Stress Disorder: A Promising Case of Preclinical-Clinical Translation? Biol Psychiatry 2022; 91 (3) : 262-272. Bassir Nia A, Bender R, Harpaz-Rotem I. Endocannabinoid System Alterations in Posttraumatic Stress Disorder: A Review of Developmental and Accumulative Effects of Trauma. Chronic Stress (Thousand Oaks) 2019; 3 . Tables Table 1: The baseline characteristics of participants. CT (N=22) HC (N=22) p vlaue 1 # of female participants; n(%) 4 (18.2%) 4 (18.2%) 1.00 Age; mean(SD) 42.5 (10.1) 39.4 (7.93) 0.251 BMI; mean(SD) 29.8 (6.22) 27.6 (5.14) 0.214 Tracer dose; mCi; mean(SD) 12.8 (4.16) 13.8 (4.00) 0.553 Tracer mass; µg/kg; mean(SD) 0.03 (0.02) 0.03 (0.02) 0.682 Current PTSD; n (%) 8 (36.4%) - # of traumatic events; n(%) 19.0 (33.4) - Nicotine dependence; n (%) 2 (9.09%) - - FTND Score 2 ; mean (SD) 4.5 (0.5) - - Current MDD; n(%) 7 (38.9%) Current antidepressant use; n (%) 6 (27.3%) - - Current benzodiazepine use; n (%) 1 (4.5%) - - Abbreviations: BMI, Body Mass Index; FTND, Fagerstrom Test for Nicotine Dependence; MDD, Major Depressive Disorder; PTSD, Post-Traumatic Stress Disorder. 1 T test (continuous) and Chi-square test (categorical). 2 In those with nicotine dependence. Table 2: Estimated LS Means of [¹¹C]OMAR VT and LMM-Derived Statistics for Secondary Regions. LS mean (SE) Contrast % F P SD Sidak CT HC Caudate 0.94 (0.047) 1.11 (0.047) -15.3% F (1,42) = 6.48 0.14 ACC 1.32 (0.053) 1.49 (0.053) -11.4% F (1,42) = 5.02 0.22 PCC 0.99 (0.050) 1.10 (0.050) -10.0% F (1,42) = 2.15 0.32 Cerebellum 1.16 (0.045) 1.27 (0.045) -8.6% F (1,42) = 3.41 0.32 Insula 1.30 (0.056) 1.46 (0.056) -10.9% F (1,42) = 4.04 0.31 Occipital 1.17 (0.050) 1.30 (0.050) -10.0% F (1,42) = 3.49 0.32 Parietal 1.21 (0.052) 1.30 (0.052) -6.9% F (1,42) = 1.69 0.32 Putamen 1.34 (0.056) 1.53 (0.056) -12.4% F (1,42) = 5.55 0.19 Temporal 1.25 (0.051) 1.38 (0.051) -9.4% F (1,42) = 3.68 0.32 Thalamus 0.94 (0.040) 1.04 (0.040) -9.6% F (1,42) = 2.84 0.32 Abbreviations: ACC, Anterior Cingulate Cortex; PCC; Posterior Cingulate Cortex Additional Declarations Yes Anahita Bassir Nia is a member of the Scientific Advisory Board of Synendos Therapeutics AG, Switzerland. Marc Potenza has consulted for Boehringer Ingelheim and Baria-Tek; has been involved in a patent application with Yale University and Novartis; has received research support (to Yale) from Mohegan Sun Casino and the Connecticut Council on Problem Gambling; has participated in surveys, mailings, or telephone consultations related to internet use, addictions, impulse-control disorders or other health topics; has consulted for and/or advised gambling, non-profit, healthcare and legal entities on issues related to impulse control, internet use and addictive disorders; has performed grant reviews for research funding agencies; has edited journals and journal sections; has given academic lectures in grand rounds, CME events, and other clinical or scientific venues; and has generated books or book chapters for publishers of mental health texts. Deepak Cyril D’Souza currently receives or has received research support in the past 3 years from Takeda, Boehringer Ingelheim, Jazz, Biogen, and Cerevel, administered through Yale University School of Medicine. Deepak Cyril D’Souza has served as a consultant for Jazz, Bio Haven, Atai, Abide, France Foundation currently or in the past 3 years. Patents: 1) Emmanuelle Schindler and Deepak Cyril D’Souza: Use of Psilocybin in Headache Disorders, 2) Deepak Cyril D’Souza: Use of Dimethyltryptamine in the treatment of Depression. Ilan Harpaz-Rotem receives funding from Boehringer Ingelheim via Investigator-Initiated Research (IIR) for Precision Psychiatry. The rest of the authors have no financial conflicts of interest to report. Cite Share Download PDF Status: Under Review Version 1 posted Editorial decision: revise 09 Sep, 2025 Review # 2 received at journal 10 Jul, 2025 Reviewer # 2 agreed at journal 25 Jun, 2025 Review # 1 received at journal 19 Jun, 2025 Reviewer # 1 agreed at journal 30 May, 2025 Reviewers invited by journal 27 May, 2025 Editor assigned by journal 29 Apr, 2025 Submission checks completed at journal 29 Apr, 2025 First submitted to journal 28 Apr, 2025 Unknown event 28 Apr, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-6536815","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":462814202,"identity":"7c091827-288a-4970-9cf0-e10bf43c397c","order_by":0,"name":"ANAHITA BASSIR NIA","email":"data:image/png;base64,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","orcid":"https://orcid.org/0000-0002-3890-3518","institution":"Yale University School of Medicine,","correspondingAuthor":true,"prefix":"","firstName":"ANAHITA","middleName":"BASSIR","lastName":"NIA","suffix":""},{"id":462814203,"identity":"bf96b7b4-80c4-4564-8db3-928cbe06c62a","order_by":1,"name":"Ardavan Mohammad Aghaei","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Ardavan","middleName":"Mohammad","lastName":"Aghaei","suffix":""},{"id":462814204,"identity":"1073baa0-c5b6-4899-8e4a-70382c82f812","order_by":2,"name":"Brian Pittman","email":"","orcid":"","institution":"Yale School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Brian","middleName":"","lastName":"Pittman","suffix":""},{"id":462814205,"identity":"c3324bad-8ccd-44a1-9b1d-89313536039b","order_by":3,"name":"Nachshon Korem","email":"","orcid":"https://orcid.org/0000-0003-1859-2668","institution":"Yaly university","correspondingAuthor":false,"prefix":"","firstName":"Nachshon","middleName":"","lastName":"Korem","suffix":""},{"id":462814206,"identity":"fd0ae14d-66e0-49a3-8847-0d8e96f78883","order_by":4,"name":"Deepak D'Souza","email":"","orcid":"https://orcid.org/0000-0003-3141-1462","institution":"Yale University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Deepak","middleName":"","lastName":"D'Souza","suffix":""},{"id":462814207,"identity":"e252f6e6-f8b5-476b-9561-83e9cf88312f","order_by":5,"name":"Marc Potenza","email":"","orcid":"https://orcid.org/0000-0002-6323-1354","institution":"Yale university","correspondingAuthor":false,"prefix":"","firstName":"Marc","middleName":"","lastName":"Potenza","suffix":""},{"id":462814208,"identity":"34822896-41a2-4d36-8770-634e2b1230f2","order_by":6,"name":"Ansel Hillmer","email":"","orcid":"https://orcid.org/0000-0002-8105-1381","institution":"Yale University","correspondingAuthor":false,"prefix":"","firstName":"Ansel","middleName":"","lastName":"Hillmer","suffix":""},{"id":462814209,"identity":"6d42db47-43ea-4f5d-a78a-b9c691adc46c","order_by":7,"name":"Mohini Ranganathan","email":"","orcid":"https://orcid.org/0000-0002-8412-2923","institution":"Yale University","correspondingAuthor":false,"prefix":"","firstName":"Mohini","middleName":"","lastName":"Ranganathan","suffix":""},{"id":462814210,"identity":"334438c9-2149-4e38-b4e1-7982e09a2b49","order_by":8,"name":"Ilan Harpaz-Rotem","email":"","orcid":"https://orcid.org/0000-0002-6066-9406","institution":"Yale University","correspondingAuthor":false,"prefix":"","firstName":"Ilan","middleName":"","lastName":"Harpaz-Rotem","suffix":""}],"badges":[],"createdAt":"2025-04-26 20:20:07","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-6536815/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-6536815/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":83648462,"identity":"6928b3cd-30ca-4c5f-a1a9-dfdd7017b994","added_by":"auto","created_at":"2025-05-30 06:21:55","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":165008,"visible":true,"origin":"","legend":"\u003cp\u003e[\u003csup\u003e11\u003c/sup\u003eC]OMAR volume of distribution LS mean (standard error) as a global composite value and in the three PTSD-related ROIs.\u003c/p\u003e","description":"","filename":"floatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-6536815/v1/e52459aa3ec9733dbfab3a42.png"},{"id":83649139,"identity":"9d8ee56f-b7f5-442d-a96e-66b142d1b390","added_by":"auto","created_at":"2025-05-30 06:37:55","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1104133,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-6536815/v1/6b22dbd0-5eb2-407f-b3f3-04fc36124960.pdf"}],"financialInterests":"\u003cb\u003eYes\u003c/b\u003e\nAnahita Bassir Nia is a member of the Scientific Advisory Board of Synendos Therapeutics AG, Switzerland. Marc Potenza has consulted for Boehringer Ingelheim and Baria-Tek; has been involved in a patent application with Yale University and Novartis; has received research support (to Yale) from Mohegan Sun Casino and the Connecticut Council on Problem Gambling; has participated in surveys, mailings, or telephone consultations related to internet use, addictions, impulse-control disorders or other health topics; has consulted for and/or advised gambling, non-profit, healthcare and legal entities on issues related to impulse control, internet use and addictive disorders; has performed grant reviews for research funding agencies; has edited journals and journal sections; has given academic lectures in grand rounds, CME events, and other clinical or scientific venues; and has generated books or book chapters for publishers of mental health texts. Deepak Cyril D’Souza currently receives or has received research support in the past 3 years from Takeda, Boehringer Ingelheim, Jazz, Biogen, and Cerevel, administered through Yale University School of Medicine. Deepak Cyril D’Souza has served as a consultant for Jazz, Bio Haven, Atai, Abide, France Foundation currently or in the past 3 years. Patents: 1) Emmanuelle Schindler and Deepak Cyril D’Souza: Use of Psilocybin in Headache Disorders, 2) Deepak Cyril D’Souza: Use of Dimethyltryptamine in the treatment of Depression. Ilan Harpaz-Rotem receives funding from Boehringer Ingelheim via Investigator-Initiated Research (IIR) for Precision Psychiatry. The rest of the authors have no financial conflicts of interest to report.","formattedTitle":"Cannabinoid Receptor Type 1 Availability in Individuals with a History of Childhood Trauma: A Positron Emission Tomography Study","fulltext":[{"header":"Introduction","content":"\u003cp\u003eChildhood trauma (CT), defined as exposure to significant traumatic events before the age of 18, has profound impacts on mental health [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. Individuals who experience CT are at higher risk of developing several psychiatric disorders, including depression and post-traumatic stress disorder (PTSD) [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. CT exposure has been reported to lead to structural and functional alterations in the nervous system, resulting in long-lasting consequences [\u003cspan additionalcitationids=\"CR5 CR6\" citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e–\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. CT typically imposes threats to survival, body integrity, or sense of self, which explains the significant alterations in the ‘threat-detection and response circuit’, particularly the hippocampus, amygdala, and prefrontal cortex (PFC), in individuals with a history of CT [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe endocannabinoid (eCB) system, which has a central role in stress response [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e], is impacted by various forms of trauma and chronic stress [\u003cspan additionalcitationids=\"CR10 CR11 CR12\" citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e–\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. Trauma-induced reductions in cannabinoid receptor type 1 (CB1R), the most abundant G-protein coupled receptor in the brain, have been reported in animal models of early life adversity, such as maternal deprivation and social isolation [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]; these findings persist into adulthood [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. Similarly, animal models of chronic stress have reported lower levels of CB1Rs in various brain regions, including the hippocampus [\u003cspan additionalcitationids=\"CR10 CR11 CR12\" citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e–\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eDespite this evidence from animal studies, the exact impact of CT on the eCB system in humans remains unclear. Human studies on the impact of trauma on the eCB system have predominantly focused on peripheral eCB levels and reported lower peripheral levels of 2-arachidonoyl glycerol (2-AG) and Anandamide (AEA) in those with trauma-related psychiatric disorders [\u003cspan additionalcitationids=\"CR18\" citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e–\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. However, they often did not specifically address CT. In contrast, a few studies that investigated peripheral eCBs in individuals with CT reported higher hair levels of 1-arachidonoylglycerol (1-AG) [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e], and higher plasma levels of an eCB-related compound, oleoylethanolamide (OEA) [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e]. While these studies provide valuable evidence on the unique long-lasting impact of CT on the eCB system, peripheral eCB levels can originate from various sources [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e], and are not correlated with central eCBs [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e]. The impact of CT on the central eCB system in humans has not been reported.\u003c/p\u003e \u003cp\u003eCB1Rs are principal components of the eCB system that can be measured \u003cem\u003ein vivo\u003c/em\u003e using PET imaging and the CB1R specific radiotracers, such as [11C]OMAR [\u003cspan additionalcitationids=\"CR25 CR26\" citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e–\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e]. In this study, for the first time, we aimed to compare CB1R availability in adult humans with and without CT histories. Consistent with evidence from animal models [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e], we hypothesized to observe a lower CB1R availability in individuals with a history of CT versus healthy controls with no history of CT (HC), both at a whole-brain level, and in three specific brain regions that express high levels of CB1R and are largely affected by CT, i.e., amygdala, hippocampus, and frontal cortex [\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e].\u003c/p\u003e \u003cp\u003e\u003c/p\u003e \u003cp\u003e\u003c/p\u003e \u003cp\u003e\u003c/p\u003e \u003cp\u003e\u003c/p\u003e"},{"header":"Methods","content":"\u003cp\u003e\u003cstrong\u003eParticipants:\u003c/strong\u003e Adult men and women (age \u0026ge; 18) with CT histories (n=22) comprised a CT group, and age- and sex-matched healthy individuals without CT histories served as the HC group (n=22). All individuals received detailed information about the study and signed written informed consent. Inclusion in the CT group was determined based on exposure to a major traumatic event based on Criterion A of the DSM-5 criteria for PTSD, assessed by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) or Structured Clinical Interview for DSM-5 Disorders (SCID-5), and exposure to traumatic events for the first time before the age of 18, assessed by the Trauma Questionnaire (TQ) and Childhood Trauma Questionnaire (CTQ) [29-32]. Nicotine dependence was assessed using the Fagerstrom Test for Nicotine Dependence (FTND) [33]. Exclusion criteria included severe mental illness (e.g., schizophrenia), current substance use disorder (excluding nicotine), recent cannabis use, use of anticoagulants, and any medical condition that could interfere with the study, as determined by the primary investigator. The study protocol was approved by the institutional review boards of Yale School of Medicine and the VA Connecticut Health Care System. Additional HCs were included from our group\u0026rsquo;s previously published research investigating CB1R availability in individuals with other psychiatric disorders [34, 35].\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eRadiochemistry and Imaging:\u003c/strong\u003e Eligible participants underwent structural Magnetic Resonance Imaging (MRI) using a Siemens 3T system (Siemens Medical Solutions, Malvern, Pennsylvania). Standard T1-weighted anatomical sequences were obtained to exclude anatomical abnormalities and to co-register with PET scan images. [\u003csup\u003e11\u003c/sup\u003eC]OMAR, a specific CB1R tracer, was used to measure CB1R availability. [\u003csup\u003e11\u003c/sup\u003eC]OMAR was synthesized with high molar activity according to a previously published protocol adapted to the TRACERlab FXC Pro automated synthesis module (GE Healthcare, Milwaukee, WI) [36]. Dynamic PET scans were acquired using a High Resolution Research Tomograph (HRRT, Siemens Medical Systems, Knoxville, TN) in 3D mode. Imaging started with a six-minute transmission scan used for attenuation correction. Subsequently, participants were scanned for 120 minutes following an intravenous bolus injection of 12.8 (4.16) mCi [\u003csup\u003e11\u003c/sup\u003eC]OMAR over a period of one minute. To account for motion, an optical system (Polaris Vicra, Northern Digital Incorporated, Waterloo, Ontario, Canada) was positioned behind the PET scanner to track the position of an infrared reflective tool mounted on the participant\u0026rsquo;s head. An arterial line was placed prior to the scan with arterial blood sampling acquired throughout the imaging session. Blood samples collected at 5, 15, 30, 60, 90, and 120 minutes post-injection were analyzed using column-switching high-performance liquid chromatography (HPLC) to measure the unmetabolized parent tracer fraction for calculation of the metabolite-corrected arterial plasma input function [37, 38].\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eImage Processing:\u003c/strong\u003e Consistent with previous work, dynamic list mode data were reconstructed and corrected for attenuation, normalization, scatter, randoms, dead time, and motion using the ordered subset-expectation maximization (OSEM) algorithm [39]. Subsequently, PET images were registered to the participant\u0026rsquo;s MR anatomical image and then to an MR template image [40]. Anatomical Automatic Labeling (AAL) was used to define thirteen regions of interest (ROIs), namely amygdala, caudate, cerebellum, anterior cingulate cortex, posterior cingulate cortex, frontal, hippocampus, insula, occipital, parietal, putamen, temporal, and thalamus [41]. Partial volume correction was also applied using a method similar to previous studies [40, 42]. Time-activity curves for each ROI were extracted, and multilinear analysis-1 (t* = 30 min) was used to estimate [\u003csup\u003e11\u003c/sup\u003eC]OMAR \u003cem\u003eV\u003csub\u003eT\u003c/sub\u003e\u003c/em\u003e in each region [43].\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eStatistical Analysis:\u003c/strong\u003e All outcomes were assessed for normality using normal probability plots and Kolmogorov-Smirnov tests. Similar to previous studies [19, 34, 44], a global composite of CB1R availability was calculated by averaging [\u003csup\u003e11\u003c/sup\u003eC]OMAR \u003cem\u003eV\u003csub\u003eT\u003c/sub\u003e\u003c/em\u003e across all 13 study regions and served as a primary outcome and was compared between groups (CT vs HC) using a linear model. Additionally, three ROIs (amygdala, frontal cortex, and hippocampus) were selected as primary outcomes, given the evidence on the heavy impact of CT on these regions [7]. These were analyzed using a linear mixed model (LMM) with group as a between-subjects factor and region as a within-subjects factor. The interaction was modeled, and the correlation between observations measured repeatedly within each subject was modeled using structured variance-covariance matrices. The best-fitting model was selected according to information criteria, and residual plots confirmed model fit. Least-square (LS) means were estimated and compared post-hoc. The rest of the ten ROIs were considered as exploratory outcomes and were analyzed using similar LMMs. Previous studies have suggested that age, sex, and body mass index (BMI) relate to CB1R availability in some ROIs [40]; therefore, these were assessed in each model. However, their inclusion did not alter the model results and had no significant effect on the outcomes, and thus, they were dropped from the model for parsimony. Potential effects of clinical factors within CT (current psychiatric diagnosis, medication use, number of trauma events, nicotine dependence) on global CB1R were assessed using similar linear models as described above. \u0026nbsp;All primary outcomes were tested using a two-sided alpha=0.05 significance threshold. For exploratory analyses testing for group differences in secondary regions and for the effects of clinical factors within the CT group, Type I error was corrected using the less conservative step-down (SD) Sidak adjustment [45]. All analyses were conducted using SAS, version 9.4 (SAS Institute Inc., Cary, NC, USA).\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003e\u003cstrong\u003eBaseline characteristics.\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAge, sex, BMI, and the dose and mass of the tracer injected during the PET imaging were similar between groups (Table 1). Of the 22 participants with CT, 8 met criteria for current posttraumatic stress disorder (PTSD), and 7 met criteria for current major depressive disorder (MDD, 6 of whom had both MDD and PTSD) (based on SCID-5). Six individuals with CT were taking antidepressant medications.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCB1R availability in the CT versus HC groups.\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eLower composite CB1R availability was observed in the CT versus HC groups (difference -11.36%, F\u003csub\u003e(1,42)\u003c/sub\u003e=4.35; p = 0.04, d = 0.63). In the LMM examining the pre-selected 3 PTSD-relevant ROIs, the group-by-region interactions was significant (\u003cem\u003eF\u003csub\u003e(2,84)\u003c/sub\u003e\u003c/em\u003e=4.49, p=0.014) driving by lower CB1R availability among CT participants in the amygdala (-13.70%,\u003cem\u003e\u0026nbsp;F\u003csub\u003e(1,84)\u003c/sub\u003e\u003c/em\u003e=6.66, p=0.01, d=0.72) and hippocampus (-14.50%,\u003cem\u003e\u0026nbsp;F\u003csub\u003e(1,84)\u003c/sub\u003e\u003c/em\u003e=6.59, p=0.01, d=0.78), but not in the frontal region (-8.08%,\u003cem\u003e\u0026nbsp;F\u003csub\u003e(1,84)\u003c/sub\u003e\u003c/em\u003e=2.17, p=0.14, d=0.47) (Figure1). In the exploratory analysis of other ROIs, no statistically significant differences were observed (Table 2).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eThe effect of clinical factors on global CB1R availability among CT\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThere was no difference in CB1R availability based on meeting criteria for PTSD (\u003cem\u003eF\u003csub\u003e(1,20)\u003c/sub\u003e\u003c/em\u003e=4.01, p\u003csub\u003eSD Sidak\u003c/sub\u003e=0.27) or MDD (\u003cem\u003eF\u003csub\u003e(1,20)\u003c/sub\u003e\u003c/em\u003e=4.11, p\u003csub\u003eSD Sidak\u003c/sub\u003e=0.27). On average, CT participants reported encountering 19.0 \u0026plusmn; 33.4 traumatic events in their lifetime, and event frequency was not associated with CB1R availability (Spearman r = -0.05, p\u003csub\u003eSD Sidak\u0026nbsp;\u003c/sub\u003e= 0.84). No differences were observed between participants who were or were not taking antidepressant medications (\u003cem\u003eF\u003csub\u003e(1,20)\u003c/sub\u003e\u003c/em\u003e=2.63, p\u003csub\u003eSD Sidak\u003c/sub\u003e=0.32). While there was no significant difference in CB1R availability between tobacco users and non-users (\u003cem\u003eF\u003csub\u003e(1,20)\u003c/sub\u003e\u003c/em\u003e=0.51, p\u003csub\u003eSD Sidak\u003c/sub\u003e=0.71), this result should be interpreted with caution, as only two CT participants reported smoking.\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eWhole-brain CB1R availability is lower in adults with a history of CT compared to controls with a reduction in specific regions, including the hippocampus and amygdala. To the best of our knowledge, this is the first report on the \u003cem\u003ein vivo\u003c/em\u003e CB1R availability in adult humans with CT. Our main finding aligns with most preclinical studies that have reported lower CB1R immunoreactivity, expression levels, or binding following early life stressors in various brain regions, especially the hippocampus, with findings persisting into adulthood [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan additionalcitationids=\"CR47\" citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e]. However, not all preclinical studies have reported such findings [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e, \u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eBoth animal and human studies have demonstrated that CB1R expression gradually increases during early childhood, reaches its maximum in adolescence, and then drops to stable levels in early adulthood [\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e]. Thus, exposure to CT, when the eCB system is still immature, could disrupt the normal development of the main elements of the eCB system, such as CB1R. In addition, the eCB system and the hypothalamic-pituitary-adrenal (HPA) axis interact closely in the initiation and termination of stress responses [\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e]. CT has been shown to dysregulate the coupling of the glucocorticoid and eCB systems, leading to impaired regulation of stress responses by glucocorticoids [\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e]. Chronic stress typically induces downregulation of presynaptic CB1Rs, which is likely due to the activation of genomic glucocorticoid receptors and could be blocked by glucocorticoid receptor antagonists [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e, \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. While the precise mechanisms for glucocorticoid receptor activation leading to downregulation of CB1Rs are not fully understood, two mechanisms have been proposed [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]: 1) direct negative regulation of the CB1R gene by glucocorticoids [\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e], or 2) glucocorticoid-mediated recruitment of eCB signaling, resulting in agonist-induced receptor desensitization, as observed with sustained 2-AG signaling elevation [\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eConsiderable research has focused on the potential role of epigenetic programming in the delayed effects of CT on the eCB system. These studies generally indicate that CT has a persistent impact on gene expression and behavior through epigenetic mechanisms, with the HPA axis and glucocorticoid receptors being among the most consistently affected systems. A systematic review reported that CT, both in animal models and human studies, results in increased methylation and lower expression of glucocorticoid receptors [\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e]. This implies glucocorticoid resistance and dysregulation of the HPA axis response to stress in adulthood [\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e, \u003cspan citationid=\"CR56\" class=\"CitationRef\"\u003e56\u003c/span\u003e]. Other studies indicate that CT impairs the coupling of the glucocorticoid and eCB systems in the hippocampus, resulting in impaired stress regulation later in life [\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e]. Moreover, genetic studies have found significant interactions between CT, particularly sexual abuse, and eCB-related gene polymorphisms in amygdala-related stress habituation and symptoms of cannabis use disorder [\u003cspan citationid=\"CR57\" class=\"CitationRef\"\u003e57\u003c/span\u003e, \u003cspan citationid=\"CR58\" class=\"CitationRef\"\u003e58\u003c/span\u003e]. Our findings support the potential specific impact of CT on the eCB system, which may differ from the effects of trauma exposure when it occurs during adulthood.\u003c/p\u003e \u003cp\u003eFuture directions: Further studies are required to replicate these findings and investigate the clinical implications of low CB1R availability in individuals with a history of CT. The availability of cannabinoids and the recent development of eCB modulators make it possible now to target the eCB system in recovery from CT [\u003cspan citationid=\"CR59\" class=\"CitationRef\"\u003e59\u003c/span\u003e]. Moreover, given the critical development of the eCB system in adolescence, future studies should investigate the differential impact of trauma exposure during early childhood versus adolescence. The effects of other factors, such as the cumulative effects of major traumatic events and chronic stress, or the types of trauma, are also important to investigate.\u003c/p\u003e\n\u003ch3\u003eLimitations\u003c/h3\u003e\n\u003cp\u003eStudy limitations warrant consideration. First, the sample size was small, but within the range of other published exploratory PET imaging studies on the eCB system [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e, \u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e, \u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e]. Nevertheless, these preliminary findings warrant further research with larger sample sizes and more granular information on CT to investigate the impact of various trauma-related factors. Second, the small sample size did not allow for the investigation of sex differences. Sex differences in the eCB system and stress responses have been reported [\u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e60\u003c/span\u003e]. Future research should address potential sex differences in CB1R availability among individuals with CT histories. Third, not all HC participants completed questionnaires related to childhood trauma, and the extent of childhood trauma was not fully assessed in all cases. However, any history of CT in a subset of the HCs would likely attenuate rather than inflate the main findings. Lastly, we did not investigate the clinical impact of lower CB1R availability in individuals with CT histories. Further studies are needed to examine how low CB1R availability in individuals with CT histories may relate to stress responses or clinical symptoms.\u003c/p\u003e"},{"header":"Conclusions","content":"\u003cp\u003eThis exploratory study showed lower CB1R availability in individuals with a history of CT, raising the intriguing possibility of targeting the eCB in the treatment of CT consequences on mental health.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgments\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis work was supported by the National Center for PTSD (NCPTSD), VA Healthcare Medical Center, National Institute of Drug Abuse Grant No. 21DA030702-01A1, National Institute of Mental Health Grant No. R21MH094961, and VA CSR\u0026amp;D Merit Award CX-001538.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConflict of Interest\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAnahita Bassir Nia is a member of the Scientific Advisory Board of Synendos Therapeutics AG, Switzerland. Marc Potenza has consulted for Boehringer Ingelheim and Baria-Tek; has been involved in a patent application with Yale University and Novartis; has received research support (to Yale) from Mohegan Sun Casino and the Connecticut Council on Problem Gambling; has participated in surveys, mailings, or telephone consultations related to internet use, addictions, impulse-control disorders or other health topics; has consulted for and/or advised gambling, non-profit, healthcare and legal entities on issues related to impulse control, internet use and addictive disorders; has performed grant reviews for research funding agencies; has edited journals and journal sections; has given academic lectures in grand rounds, CME events, and other clinical or scientific venues; and has generated books or book chapters for publishers of mental health texts. Deepak Cyril D\u0026rsquo;Souza currently receives or has received research support in the past 3 years from Takeda, Boehringer Ingelheim, Jazz, Biogen, and Cerevel, administered through Yale University School of Medicine. Deepak Cyril D\u0026rsquo;Souza has served as a consultant for Jazz, Bio Haven, Atai, Abide, France Foundation currently or in the past 3 years. Patents: 1) Emmanuelle Schindler and Deepak Cyril D\u0026rsquo;Souza: Use of Psilocybin in Headache Disorders, 2) Deepak Cyril D\u0026rsquo;Souza: Use of Dimethyltryptamine in the treatment of Depression. Ilan Harpaz-Rotem receives funding from \u003cem\u003eBoehringer Ingelheim\u003c/em\u003e via Investigator-Initiated Research (IIR) for Precision Psychiatry. The rest of the authors have no financial conflicts of interest to report.\u0026nbsp;\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eLippard ETC, Nemeroff CB. The Devastating Clinical Consequences of Child Abuse and Neglect: Increased Disease Vulnerability and Poor Treatment Response in Mood Disorders. \u003cem\u003eAm J Psychiatry\u003c/em\u003e 2020; \u003cstrong\u003e177\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e20-36.\u003c/li\u003e\n\u003cli\u003eSun J, Patel F, Rose-Jacobs R, Frank DA, Black MM, Chilton M. Mothers\u0026rsquo; adverse childhood experiences and their young children\u0026rsquo;s development. \u003cem\u003eAmerican journal of preventive medicine\u003c/em\u003e 2017; \u003cstrong\u003e53\u003c/strong\u003e(6)\u003cstrong\u003e: \u003c/strong\u003e882-891.\u003c/li\u003e\n\u003cli\u003eBrady KT, Back SE. Childhood trauma, posttraumatic stress disorder, and alcohol dependence. \u003cem\u003eAlcohol research: current reviews\u003c/em\u003e 2012; \u003cstrong\u003e34\u003c/strong\u003e(4)\u003cstrong\u003e: \u003c/strong\u003e408.\u003c/li\u003e\n\u003cli\u003eAnacker C, O\u0026apos;Donnell KJ, Meaney MJ. Early life adversity and the epigenetic programming of hypothalamic-pituitary-adrenal function. \u003cem\u003eDialogues in clinical neuroscience\u003c/em\u003e 2014; \u003cstrong\u003e16\u003c/strong\u003e(3)\u003cstrong\u003e: \u003c/strong\u003e321-333.\u003c/li\u003e\n\u003cli\u003eDanese A, Moffitt TE, Harrington H, Milne BJ, Polanczyk G, Pariante CM\u003cem\u003e et al.\u003c/em\u003e Adverse childhood experiences and adult risk factors for age-related disease: depression, inflammation, and clustering of metabolic risk markers. \u003cem\u003eArchives of pediatrics \u0026amp; adolescent medicine\u003c/em\u003e 2009; \u003cstrong\u003e163\u003c/strong\u003e(12)\u003cstrong\u003e: \u003c/strong\u003e1135-1143.\u003c/li\u003e\n\u003cli\u003eDanese A, McEwen BS. Adverse childhood experiences, allostasis, allostatic load, and age-related disease. \u003cem\u003ePhysiology \u0026amp; behavior\u003c/em\u003e 2012; \u003cstrong\u003e106\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e29-39.\u003c/li\u003e\n\u003cli\u003eTeicher MH, Samson JA, Anderson CM, Ohashi K. The effects of childhood maltreatment on brain structure, function and connectivity. \u003cem\u003eNat Rev Neurosci\u003c/em\u003e 2016; \u003cstrong\u003e17\u003c/strong\u003e(10)\u003cstrong\u003e: \u003c/strong\u003e652-666.\u003c/li\u003e\n\u003cli\u003eMorena M, Patel S, Bains JS, Hill MN. Neurobiological Interactions Between Stress and the Endocannabinoid System. \u003cem\u003eNeuropsychopharmacology\u003c/em\u003e 2016; \u003cstrong\u003e41\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e80-102.\u003c/li\u003e\n\u003cli\u003eHill MN, Patel S, Carrier EJ, Rademacher DJ, Ormerod BK, Hillard CJ\u003cem\u003e et al.\u003c/em\u003e Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. \u003cem\u003eNeuropsychopharmacology\u003c/em\u003e 2005; \u003cstrong\u003e30\u003c/strong\u003e(3)\u003cstrong\u003e: \u003c/strong\u003e508-515.\u003c/li\u003e\n\u003cli\u003eHill MN, Carrier EJ, McLaughlin RJ, Morrish AC, Meier SE, Hillard CJ\u003cem\u003e et al.\u003c/em\u003e Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. \u003cem\u003eJ Neurochem\u003c/em\u003e 2008; \u003cstrong\u003e106\u003c/strong\u003e(6)\u003cstrong\u003e: \u003c/strong\u003e2322-2336.\u003c/li\u003e\n\u003cli\u003eHu W, Zhang M, Cz\u0026eacute;h B, Zhang W, Fl\u0026uuml;gge G. Chronic restraint stress impairs endocannabinoid mediated suppression of GABAergic signaling in the hippocampus of adult male rats. \u003cem\u003eBrain Res Bull\u003c/em\u003e 2011; \u003cstrong\u003e85\u003c/strong\u003e(6)\u003cstrong\u003e: \u003c/strong\u003e374-379.\u003c/li\u003e\n\u003cli\u003eWamsteeker JI, Kuzmiski JB, Bains JS. Repeated stress impairs endocannabinoid signaling in the paraventricular nucleus of the hypothalamus. \u003cem\u003eJ Neurosci\u003c/em\u003e 2010; \u003cstrong\u003e30\u003c/strong\u003e(33)\u003cstrong\u003e: \u003c/strong\u003e11188-11196.\u003c/li\u003e\n\u003cli\u003eRossi S, De Chiara V, Musella A, Kusayanagi H, Mataluni G, Bernardi G\u003cem\u003e et al.\u003c/em\u003e Chronic psychoemotional stress impairs cannabinoid-receptor-mediated control of GABA transmission in the striatum. \u003cem\u003eJ Neurosci\u003c/em\u003e 2008; \u003cstrong\u003e28\u003c/strong\u003e(29)\u003cstrong\u003e: \u003c/strong\u003e7284-7292.\u003c/li\u003e\n\u003cli\u003eSu\u0026aacute;rez J, Llorente R, Romero-Zerbo SY, Mateos B, Berm\u0026uacute;dez-Silva FJ, de Fonseca FR\u003cem\u003e et al.\u003c/em\u003e Early maternal deprivation induces gender-dependent changes on the expression of hippocampal CB(1) and CB(2) cannabinoid receptors of neonatal rats. \u003cem\u003eHippocampus\u003c/em\u003e 2009; \u003cstrong\u003e19\u003c/strong\u003e(7)\u003cstrong\u003e: \u003c/strong\u003e623-632.\u003c/li\u003e\n\u003cli\u003eAlteba S, Korem N, Akirav I. Cannabinoids reverse the effects of early stress on neurocognitive performance in adulthood. \u003cem\u003eLearning \u0026amp; Memory\u003c/em\u003e 2016; \u003cstrong\u003e23\u003c/strong\u003e(7)\u003cstrong\u003e: \u003c/strong\u003e349-358.\u003c/li\u003e\n\u003cli\u003eRobinson SA, Loiacono RE, Christopoulos A, Sexton PM, Malone DT. The effect of social isolation on rat brain expression of genes associated with endocannabinoid signaling. \u003cem\u003eBrain Res\u003c/em\u003e 2010; \u003cstrong\u003e1343: \u003c/strong\u003e153-167.\u003c/li\u003e\n\u003cli\u003eHill MN, Bierer LM, Makotkine I, Golier JA, Galea S, McEwen BS\u003cem\u003e et al.\u003c/em\u003e Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the World Trade Center attacks. \u003cem\u003ePsychoneuroendocrinology\u003c/em\u003e 2013; \u003cstrong\u003e38\u003c/strong\u003e(12)\u003cstrong\u003e: \u003c/strong\u003e2952-2961.\u003c/li\u003e\n\u003cli\u003eHill MN, Miller GE, Ho WS, Gorzalka BB, Hillard CJ. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. \u003cem\u003ePharmacopsychiatry\u003c/em\u003e 2008; \u003cstrong\u003e41\u003c/strong\u003e(2)\u003cstrong\u003e: \u003c/strong\u003e48-53.\u003c/li\u003e\n\u003cli\u003eNeumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng M-Q, Gujarro-Anton A\u003cem\u003e et al.\u003c/em\u003e Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. \u003cem\u003eMolecular psychiatry\u003c/em\u003e 2013; \u003cstrong\u003e18\u003c/strong\u003e(9)\u003cstrong\u003e: \u003c/strong\u003e1034-1040.\u003c/li\u003e\n\u003cli\u003eKoenig AM, Gao W, Umlauft M, Schury K, Reister F, Kirschbaum C\u003cem\u003e et al.\u003c/em\u003e Altered hair endocannabinoid levels in mothers with childhood maltreatment and their newborns. \u003cem\u003eBiol Psychol\u003c/em\u003e 2018; \u003cstrong\u003e135: \u003c/strong\u003e93-101.\u003c/li\u003e\n\u003cli\u003eSchaefer C, Enning F, Mueller JK, Bumb JM, Rohleder C, Odorfer TM\u003cem\u003e et al.\u003c/em\u003e Fatty acid ethanolamide levels are altered in borderline personality and complex posttraumatic stress disorders. \u003cem\u003eEur Arch Psychiatry Clin Neurosci\u003c/em\u003e 2014; \u003cstrong\u003e264\u003c/strong\u003e(5)\u003cstrong\u003e: \u003c/strong\u003e459-463.\u003c/li\u003e\n\u003cli\u003eHillard CJ. Circulating Endocannabinoids: From Whence Do They Come and Where are They Going? \u003cem\u003eNeuropsychopharmacology\u003c/em\u003e 2018; \u003cstrong\u003e43\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e155-172.\u003c/li\u003e\n\u003cli\u003eMinichino A, Senior M, Brondino N, Zhang SH, Godwlewska BR, Burnet PWJ\u003cem\u003e et al.\u003c/em\u003e Measuring Disturbance of the Endocannabinoid System in Psychosis: A Systematic Review and Meta-analysis. \u003cem\u003eJAMA Psychiatry\u003c/em\u003e 2019; \u003cstrong\u003e76\u003c/strong\u003e(9)\u003cstrong\u003e: \u003c/strong\u003e914-923.\u003c/li\u003e\n\u003cli\u003eWong DF, Kuwabara H, Horti AG, Raymont V, Brasic J, Guevara M\u003cem\u003e et al.\u003c/em\u003e Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. \u003cem\u003eNeuroimage\u003c/em\u003e 2010; \u003cstrong\u003e52\u003c/strong\u003e(4)\u003cstrong\u003e: \u003c/strong\u003e1505-1513.\u003c/li\u003e\n\u003cli\u003eNormandin MD, Zheng MQ, Lin KS, Mason NS, Lin SF, Ropchan J\u003cem\u003e et al.\u003c/em\u003e Imaging the cannabinoid CB1 receptor in humans with [11C]OMAR: assessment of kinetic analysis methods, test-retest reproducibility, and gender differences. \u003cem\u003eJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism\u003c/em\u003e 2015; \u003cstrong\u003e35\u003c/strong\u003e(8)\u003cstrong\u003e: \u003c/strong\u003e1313-1322.\u003c/li\u003e\n\u003cli\u003eTsujikawa T, Zoghbi SS, Hong J, Donohue SR, Jenko KJ, Gladding RL\u003cem\u003e et al.\u003c/em\u003e In vitro and in vivo evaluation of (11)C-SD5024, a novel PET radioligand for human brain imaging of cannabinoid CB1 receptors. \u003cem\u003eNeuroimage\u003c/em\u003e 2014; \u003cstrong\u003e84: \u003c/strong\u003e733-741.\u003c/li\u003e\n\u003cli\u003eNeumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng MQ, Gujarro-Anton A\u003cem\u003e et al.\u003c/em\u003e Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. \u003cem\u003eMol Psychiatry\u003c/em\u003e 2013; \u003cstrong\u003e18\u003c/strong\u003e(9)\u003cstrong\u003e: \u003c/strong\u003e1034-1040.\u003c/li\u003e\n\u003cli\u003eHarnett NG, Goodman AM, Knight DC. PTSD-related neuroimaging abnormalities in brain function, structure, and biochemistry. \u003cem\u003eExperimental neurology\u003c/em\u003e 2020; \u003cstrong\u003e330: \u003c/strong\u003e113331.\u003c/li\u003e\n\u003cli\u003eWeathers FW, Bovin MJ, Lee DJ, Sloan DM, Schnurr PP, Kaloupek DG\u003cem\u003e et al.\u003c/em\u003e The Clinician-Administered PTSD Scale for DSM\u0026ndash;5 (CAPS-5): Development and initial psychometric evaluation in military veterans. \u003cem\u003ePsychological assessment\u003c/em\u003e 2018; \u003cstrong\u003e30\u003c/strong\u003e(3)\u003cstrong\u003e: \u003c/strong\u003e383.\u003c/li\u003e\n\u003cli\u003eFirst MB, Williams JBW, Karg RS, Spitzer RL. \u003cem\u003eStructured clinical interview for DSM-5 disorders: SCID-5-CV research version\u003c/em\u003e. American Psychiatric Association Publishing Washington, DC2015.\u003c/li\u003e\n\u003cli\u003eBernstein DP, Fink L, Handelsman L, Foote J. Childhood trauma questionnaire. \u003cem\u003eAssessment of family violence: A handbook for researchers and practitioners\u003c/em\u003e 1998.\u003c/li\u003e\n\u003cli\u003eDavidson J, Smith R. Traumatic experiences in psychiatric outpatients. \u003cem\u003eJournal of traumatic stress\u003c/em\u003e 1990; \u003cstrong\u003e3: \u003c/strong\u003e459-475.\u003c/li\u003e\n\u003cli\u003eHeatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstr\u0026ouml;m test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. \u003cem\u003eBritish journal of addiction\u003c/em\u003e 1991; \u003cstrong\u003e86\u003c/strong\u003e(9)\u003cstrong\u003e: \u003c/strong\u003e1119-1127.\u003c/li\u003e\n\u003cli\u003eD\u0026apos;Souza DC, Cortes-Briones JA, Ranganathan M, Thurnauer H, Creatura G, Surti T\u003cem\u003e et al.\u003c/em\u003e Rapid Changes in CB1 Receptor Availability in Cannabis Dependent Males after Abstinence from Cannabis. \u003cem\u003eBiol Psychiatry Cogn Neurosci Neuroimaging\u003c/em\u003e 2016; \u003cstrong\u003e1\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e60-67.\u003c/li\u003e\n\u003cli\u003eNeumeister A, Normandin MD, Murrough JW, Henry S, Bailey CR, Luckenbaugh DA\u003cem\u003e et al.\u003c/em\u003e Positron emission tomography shows elevated cannabinoid cb 1 receptor binding in men with alcohol dependence. \u003cem\u003eAlcoholism: Clinical and Experimental Research\u003c/em\u003e 2012; \u003cstrong\u003e36\u003c/strong\u003e(12)\u003cstrong\u003e: \u003c/strong\u003e2104-2109.\u003c/li\u003e\n\u003cli\u003eHorti AG, Fan H, Kuwabara H, Hilton J, Ravert HT, Holt DP\u003cem\u003e et al.\u003c/em\u003e 11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors. \u003cem\u003eJournal of Nuclear Medicine\u003c/em\u003e 2006; \u003cstrong\u003e47\u003c/strong\u003e(10)\u003cstrong\u003e: \u003c/strong\u003e1689-1696.\u003c/li\u003e\n\u003cli\u003eNormandin MD, Zheng M-Q, Lin K-S, Mason NS, Lin S-F, Ropchan J\u003cem\u003e et al.\u003c/em\u003e Imaging the cannabinoid cb1 receptor in humans with [11c] omar: assessment of kinetic analysis methods, test\u0026ndash;retest reproducibility, and gender differences. \u003cem\u003eJournal of Cerebral Blood Flow \u0026amp; Metabolism\u003c/em\u003e 2015; \u003cstrong\u003e35\u003c/strong\u003e(8)\u003cstrong\u003e: \u003c/strong\u003e1313-1322.\u003c/li\u003e\n\u003cli\u003eHilton J, Yokoi F, Dannals RF, Ravert HT, Szabo Z, Wong DF. Column-switching HPLC for the analysis of plasma in PET imaging studies. \u003cem\u003eNucl Med Biol\u003c/em\u003e 2000; \u003cstrong\u003e27\u003c/strong\u003e(6)\u003cstrong\u003e: \u003c/strong\u003e627-630.\u003c/li\u003e\n\u003cli\u003eDesign of a motion-compensation OSEM list-mode algorithm for resolution-recovery reconstruction for the HRRT. \u003cem\u003eProceedings of the Nuclear Science Symposium Conference Record, 2003 IEEE\u003c/em\u003e2003. IEEE.\u003c/li\u003e\n\u003cli\u003eRadhakrishnan R, Worhunsky PD, Zheng M-Q, Najafzadeh S, Gallezot J-D, Planeta B\u003cem\u003e et al.\u003c/em\u003e Age, gender and body-mass-index relationships with in vivo CB1 receptor availability in healthy humans measured with [11C] OMAR PET. \u003cem\u003eNeuroImage\u003c/em\u003e 2022; \u003cstrong\u003e264: \u003c/strong\u003e119674.\u003c/li\u003e\n\u003cli\u003eTzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N\u003cem\u003e et al.\u003c/em\u003e Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. \u003cem\u003eNeuroimage\u003c/em\u003e 2002; \u003cstrong\u003e15\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e273-289.\u003c/li\u003e\n\u003cli\u003eGiovacchini G, Lerner A, Toczek MT, Fraser C, Ma K, DeMar JC\u003cem\u003e et al.\u003c/em\u003e Brain Incorporation of 11C-Arachidonic Acid, Blood Volume, and Blood Flow in Healthy Aging: A Study With Partial-Volume Correction. \u003cem\u003eJournal of Nuclear Medicine\u003c/em\u003e 2004; \u003cstrong\u003e45\u003c/strong\u003e(9)\u003cstrong\u003e: \u003c/strong\u003e1471-1479.\u003c/li\u003e\n\u003cli\u003eIchise M, Toyama H, Innis RB, Carson RE. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. \u003cem\u003eJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism\u003c/em\u003e 2002; \u003cstrong\u003e22\u003c/strong\u003e(10)\u003cstrong\u003e: \u003c/strong\u003e1271-1281.\u003c/li\u003e\n\u003cli\u003eRanganathan M, Cortes-Briones J, Radhakrishnan R, Thurnauer H, Planeta B, Skosnik P\u003cem\u003e et al.\u003c/em\u003e Reduced Brain Cannabinoid Receptor Availability in Schizophrenia. \u003cem\u003eBiol Psychiatry\u003c/em\u003e 2016; \u003cstrong\u003e79\u003c/strong\u003e(12)\u003cstrong\u003e: \u003c/strong\u003e997-1005.\u003c/li\u003e\n\u003cli\u003eHolland BS, Copenhaver MD. An improved sequentially rejective Bonferroni test procedure. \u003cem\u003eBiometrics\u003c/em\u003e 1987\u003cstrong\u003e: \u003c/strong\u003e417-423.\u003c/li\u003e\n\u003cli\u003eRomano-L\u0026oacute;pez A, M\u0026eacute;ndez-D\u0026iacute;az M, Ruiz-Contreras AE, Carrisoza R, Prosp\u0026eacute;ro-Garc\u0026iacute;a O. Maternal separation and proclivity for ethanol intake: a potential role of the endocannabinoid system in rats. \u003cem\u003eNeuroscience\u003c/em\u003e 2012; \u003cstrong\u003e223: \u003c/strong\u003e296-304.\u003c/li\u003e\n\u003cli\u003eHill MN, Eiland L, Lee TTY, Hillard CJ, McEwen BS. Early life stress alters the developmental trajectory of corticolimbic endocannabinoid signaling in male rats. \u003cem\u003eNeuropharmacology\u003c/em\u003e 2019; \u003cstrong\u003e146: \u003c/strong\u003e154-162.\u003c/li\u003e\n\u003cli\u003eLee TT, Hill MN. Age of stress exposure modulates the immediate and sustained effects of repeated stress on corticolimbic cannabinoid CB₁ receptor binding in male rats. \u003cem\u003eNeuroscience\u003c/em\u003e 2013; \u003cstrong\u003e249: \u003c/strong\u003e106-114.\u003c/li\u003e\n\u003cli\u003eMarco EM, Echeverry-Alzate V, L\u0026oacute;pez-Moreno JA, Gin\u0026eacute; E, Pe\u0026ntilde;asco S, Viveros MP. Consequences of early life stress on the expression of endocannabinoid-related genes in the rat brain. \u003cem\u003eBehav Pharmacol\u003c/em\u003e 2014; \u003cstrong\u003e25\u003c/strong\u003e(5-6)\u003cstrong\u003e: \u003c/strong\u003e547-556.\u003c/li\u003e\n\u003cli\u003eBara A, Ferland JN, Rompala G, Szutorisz H, Hurd YL. Cannabis and synaptic reprogramming of the developing brain. \u003cem\u003eNat Rev Neurosci\u003c/em\u003e 2021; \u003cstrong\u003e22\u003c/strong\u003e(7)\u003cstrong\u003e: \u003c/strong\u003e423-438.\u003c/li\u003e\n\u003cli\u003eHill MN, Campolongo P, Yehuda R, Patel S. Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder. \u003cem\u003eNeuropsychopharmacology\u003c/em\u003e 2018; \u003cstrong\u003e43\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e80-102.\u003c/li\u003e\n\u003cli\u003eAtsak P, Morena M, Schoenmaker C, Tabak E, Oomen CA, Jamil S\u003cem\u003e et al.\u003c/em\u003e Glucocorticoid-endocannabinoid uncoupling mediates fear suppression deficits after early - Life stress. \u003cem\u003ePsychoneuroendocrinology\u003c/em\u003e 2018; \u003cstrong\u003e91: \u003c/strong\u003e41-49.\u003c/li\u003e\n\u003cli\u003eMailleux P, Vanderhaeghen JJ. Glucocorticoid regulation of cannabinoid receptor messenger RNA levels in the rat caudate-putamen. An in situ hybridization study. \u003cem\u003eNeurosci Lett\u003c/em\u003e 1993; \u003cstrong\u003e156\u003c/strong\u003e(1-2)\u003cstrong\u003e: \u003c/strong\u003e51-53.\u003c/li\u003e\n\u003cli\u003eSchlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG\u003cem\u003e et al.\u003c/em\u003e Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. \u003cem\u003eNat Neurosci\u003c/em\u003e 2010; \u003cstrong\u003e13\u003c/strong\u003e(9)\u003cstrong\u003e: \u003c/strong\u003e1113-1119.\u003c/li\u003e\n\u003cli\u003eTurecki G, Meaney MJ. Effects of the Social Environment and Stress on Glucocorticoid Receptor Gene Methylation: A Systematic Review. \u003cem\u003eBiol Psychiatry\u003c/em\u003e 2016; \u003cstrong\u003e79\u003c/strong\u003e(2)\u003cstrong\u003e: \u003c/strong\u003e87-96.\u003c/li\u003e\n\u003cli\u003eKlengel T, Binder EB. Epigenetics of Stress-Related Psychiatric Disorders and Gene \u0026times; Environment Interactions. \u003cem\u003eNeuron\u003c/em\u003e 2015; \u003cstrong\u003e86\u003c/strong\u003e(6)\u003cstrong\u003e: \u003c/strong\u003e1343-1357.\u003c/li\u003e\n\u003cli\u003eCarey CE, Agrawal A, Zhang B, Conley ED, Degenhardt L, Heath AC\u003cem\u003e et al.\u003c/em\u003e Monoacylglycerol lipase (MGLL) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala habituation: Evidence from an endocannabinoid system-level analysis. \u003cem\u003eJ Abnorm Psychol\u003c/em\u003e 2015; \u003cstrong\u003e124\u003c/strong\u003e(4)\u003cstrong\u003e: \u003c/strong\u003e860-877.\u003c/li\u003e\n\u003cli\u003eLazary J, Eszlari N, Juhasz G, Bagdy G. Genetically reduced FAAH activity may be a risk for the development of anxiety and depression in persons with repetitive childhood trauma. \u003cem\u003eEur Neuropsychopharmacol\u003c/em\u003e 2016; \u003cstrong\u003e26\u003c/strong\u003e(6)\u003cstrong\u003e: \u003c/strong\u003e1020-1028.\u003c/li\u003e\n\u003cli\u003eMayo LM, Rabinak CA, Hill MN, Heilig M. Targeting the Endocannabinoid System in the Treatment of Posttraumatic Stress Disorder: A Promising Case of Preclinical-Clinical Translation? \u003cem\u003eBiol Psychiatry\u003c/em\u003e 2022; \u003cstrong\u003e91\u003c/strong\u003e(3)\u003cstrong\u003e: \u003c/strong\u003e262-272.\u003c/li\u003e\n\u003cli\u003eBassir Nia A, Bender R, Harpaz-Rotem I. Endocannabinoid System Alterations in Posttraumatic Stress Disorder: A Review of Developmental and Accumulative Effects of Trauma. \u003cem\u003eChronic Stress (Thousand Oaks)\u003c/em\u003e 2019; \u003cstrong\u003e3\u003c/strong\u003e.\u003c/li\u003e\n\u003c/ol\u003e"},{"header":"Tables","content":"\u003cp\u003eTable 1: The baseline characteristics of participants.\u003c/p\u003e\n\u003cdiv align=\"\"\u003e\n \u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"525\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 263px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCT (N=22)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eHC (N=22)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003ep\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;vlaue\u003csup\u003e1\u003c/sup\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 263px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e# of female participants; n(%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e4 (18.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e4 (18.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e1.00\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 263px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAge; mean(SD)\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e42.5 (10.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e39.4 (7.93)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.251\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 263px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eBMI; mean(SD)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e29.8 (6.22)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e27.6 (5.14)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.214\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 263px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTracer dose; mCi; mean(SD)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e12.8 (4.16)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e13.8 (4.00)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.553\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 263px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTracer mass; \u0026micro;g/kg; mean(SD)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e0.03 (0.02)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e0.03 (0.02)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.682\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 263px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCurrent PTSD; n (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e8 (36.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 263px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e# of traumatic events; n(%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e19.0 (33.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 263px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNicotine dependence; n (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e2 (9.09%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 263px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eFTND Score\u003csup\u003e2\u003c/sup\u003e; mean (SD)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e4.5 (0.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 263px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCurrent MDD; n(%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e7 (38.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 263px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCurrent antidepressant use; n (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e6 (27.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 263px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCurrent benzodiazepine use; n (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e1 (4.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003c/table\u003e\n\u003c/div\u003e\n\u003cp\u003eAbbreviations: BMI, Body Mass Index; FTND, Fagerstrom Test for Nicotine Dependence; MDD, Major Depressive Disorder; PTSD, Post-Traumatic Stress Disorder.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e1\u003c/sup\u003e T test (continuous) and Chi-square test (categorical).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e2\u003c/sup\u003e In those with nicotine dependence.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTable 2: Estimated LS Means of [\u0026sup1;\u0026sup1;C]OMAR VT and LMM-Derived Statistics for Secondary Regions.\u003c/p\u003e\n\u003cdiv align=\"\"\u003e\n \u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 203px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eLS mean (SE)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eContrast %\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eF\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 96px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eP\u003csub\u003eSD Sidak\u003c/sub\u003e\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003eCT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003eHC\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 96px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCaudate\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e0.94 (0.047)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e1.11 (0.047)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e-15.3%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003eF\u003csub\u003e(1,42)\u0026nbsp;\u003c/sub\u003e= 6.48\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 96px;\"\u003e\n \u003cp\u003e\u0026nbsp;0.14\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eACC\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e1.32 (0.053)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e1.49 (0.053)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e-11.4%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003eF\u003csub\u003e(1,42)\u0026nbsp;\u003c/sub\u003e= 5.02\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 96px;\"\u003e\n \u003cp\u003e\u0026nbsp;0.22\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePCC\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e0.99 (0.050)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e1.10 (0.050)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e-10.0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003eF\u003csub\u003e(1,42)\u0026nbsp;\u003c/sub\u003e= 2.15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 96px;\"\u003e\n \u003cp\u003e\u0026nbsp;0.32\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCerebellum\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e1.16 (0.045)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e1.27 (0.045)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e-8.6%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003eF\u003csub\u003e(1,42)\u0026nbsp;\u003c/sub\u003e= 3.41\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 96px;\"\u003e\n \u003cp\u003e\u0026nbsp;0.32\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eInsula\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e1.30 (0.056)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e1.46 (0.056)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e-10.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003eF\u003csub\u003e(1,42)\u0026nbsp;\u003c/sub\u003e= 4.04\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 96px;\"\u003e\n \u003cp\u003e\u0026nbsp;0.31\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eOccipital\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e1.17 (0.050)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e1.30 (0.050)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e-10.0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003eF\u003csub\u003e(1,42)\u0026nbsp;\u003c/sub\u003e= 3.49\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 96px;\"\u003e\n \u003cp\u003e\u0026nbsp;0.32\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eParietal\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e1.21 (0.052)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e1.30 (0.052)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e-6.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003eF\u003csub\u003e(1,42)\u0026nbsp;\u003c/sub\u003e= 1.69\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 96px;\"\u003e\n \u003cp\u003e0.32\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePutamen\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e1.34 (0.056)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e1.53 (0.056)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e-12.4%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003eF\u003csub\u003e(1,42)\u0026nbsp;\u003c/sub\u003e= 5.55\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 96px;\"\u003e\n \u003cp\u003e\u0026nbsp;0.19\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTemporal\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e1.25 (0.051)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e1.38 (0.051)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e-9.4%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003eF\u003csub\u003e(1,42)\u0026nbsp;\u003c/sub\u003e= 3.68\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 96px;\"\u003e\n \u003cp\u003e0.32\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 94px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eThalamus\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e0.94 (0.040)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e1.04 (0.040)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e-9.6%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003eF\u003csub\u003e(1,42)\u0026nbsp;\u003c/sub\u003e= 2.84\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 96px;\"\u003e\n \u003cp\u003e0.32\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003c/table\u003e\n\u003c/div\u003e\n\u003cp\u003eAbbreviations: ACC, Anterior Cingulate Cortex; PCC; Posterior Cingulate Cortex\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"molecular-psychiatry","isNatureJournal":false,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"mp","sideBox":"Learn more about [Molecular Psychiatry](http://www.nature.com/mp/)","snPcode":"41380","submissionUrl":"https://mts-mp.nature.com/cgi-bin/main.plex","title":"Molecular Psychiatry","twitterHandle":"@molpsychiatry","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"ejp","reportingPortfolio":"Nature AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-6536815/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-6536815/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eEarly life adversity has a lasting impact on the endocannabinoid (eCB) system based on animal models. However, the impact of early life adversity such as childhood trauma (CT) on the eCB system has not been thoroughly studied. We assessed the availability of cannabinoid receptor type 1 (CB1R) in individuals with CT compared to healthy controls without CT (HCs). Cannabinoid receptor type 1 (CB1R) availability was compared in adults with CT (N\u0026thinsp;=\u0026thinsp;22) and age- and sex-matched HCs (n\u0026thinsp;=\u0026thinsp;22), using positron emission tomography (PET) imaging with the CB1R-specific radiotracer [\u003csup\u003e11\u003c/sup\u003eC]OMAR. Using linear models, the effect of the group was assessed on global and trauma-relevant brain regions (amygdala, hippocampus, and frontal cortex). Compared to HCs, lower CB1R availability was observed in CT globally (difference= -11.36%, \u003cem\u003eF\u003c/em\u003e\u003csub\u003e\u003cem\u003e(1,42)\u003c/em\u003e\u003c/sub\u003e\u0026thinsp;=\u0026thinsp;4.35, p\u0026thinsp;=\u0026thinsp;0.04), in amygdala (-13.70%, \u003cem\u003eF\u003c/em\u003e\u003csub\u003e\u003cem\u003e(1,84)\u003c/em\u003e\u003c/sub\u003e\u0026thinsp;=\u0026thinsp;6.66, p\u0026thinsp;=\u0026thinsp;0.01), and in hippocampus (-14.50%, \u003cem\u003eF\u003c/em\u003e\u003csub\u003e\u003cem\u003e(1,84)\u003c/em\u003e\u003c/sub\u003e\u0026thinsp;=\u0026thinsp;6.59, p\u0026thinsp;=\u0026thinsp;0.01), but not in frontal cortex (-8.08%, \u003cem\u003eF\u003c/em\u003e\u003csub\u003e\u003cem\u003e(1,84)\u003c/em\u003e\u003c/sub\u003e\u0026thinsp;=\u0026thinsp;2.17, p\u0026thinsp;=\u0026thinsp;0.14). There were no effects of a diagnosis of posttraumatic stress disorder, major depressive disorder, nicotine dependence, or the use of antidepressant medication. This preliminary result of lower CB1R availability in adults with CT compared with HCs suggests eCB dysregulation associated with CT. Future studies should replicate and extend this finding and examine the potential effects of various trauma features on the eCB system.\u003c/p\u003e","manuscriptTitle":"Cannabinoid Receptor Type 1 Availability in Individuals with a History of Childhood Trauma: A Positron Emission Tomography Study","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-05-30 06:21:50","doi":"10.21203/rs.3.rs-6536815/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"revise","date":"2025-09-09T08:03:38+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"This content is not available.","date":"2025-07-10T18:27:37+00:00","index":2,"fulltext":"This content is not available."},{"type":"reviewerAgreed","content":"This content is not available.","date":"2025-06-25T13:02:32+00:00","index":2,"fulltext":"This content is not available."},{"type":"editorInvitedReview","content":"This content is not available.","date":"2025-06-19T13:56:29+00:00","index":1,"fulltext":"This content is not available."},{"type":"reviewerAgreed","content":"This content is not available.","date":"2025-05-30T17:09:51+00:00","index":1,"fulltext":"This content is not available."},{"type":"reviewersInvited","content":"","date":"2025-05-28T03:45:49+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-04-29T14:54:35+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-04-29T13:24:57+00:00","index":"","fulltext":""},{"type":"submitted","content":"Molecular Psychiatry","date":"2025-04-28T16:10:07+00:00","index":"","fulltext":""},{"type":"checksFailed","content":"","date":"2025-04-28T11:17:28+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"molecular-psychiatry","isNatureJournal":false,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"mp","sideBox":"Learn more about [Molecular Psychiatry](http://www.nature.com/mp/)","snPcode":"41380","submissionUrl":"https://mts-mp.nature.com/cgi-bin/main.plex","title":"Molecular Psychiatry","twitterHandle":"@molpsychiatry","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"ejp","reportingPortfolio":"Nature AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"f6666893-ff30-4060-a160-eda06488ba5c","owner":[],"postedDate":"May 30th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[{"id":49141842,"name":"Health sciences/Biomarkers"},{"id":49141843,"name":"Biological sciences/Neuroscience"}],"tags":[],"updatedAt":"2026-04-16T21:35:31+00:00","versionOfRecord":[],"versionCreatedAt":"2025-05-30 06:21:50","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-6536815","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-6536815","identity":"rs-6536815","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}